Country: United States
Language: English
Source: NLM (National Library of Medicine)
REPAGLINIDE (UNII: 668Z8C33LU) (REPAGLINIDE - UNII:668Z8C33LU)
Mylan Institutional Inc.
REPAGLINIDE
REPAGLINIDE 0.5 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
REPAGLINIDE- REPAGLINIDE TABLET MYLAN INSTITUTIONAL INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE REPAGLINIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR REPAGLINIDE TABLETS. REPAGLINIDE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 RECENT MAJOR CHANGES Dosage and Administration ( 2.3) 2/2017 INDICATIONS AND USAGE Repaglinide tablets are a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1) Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1) DOSAGE AND ADMINISTRATION The recommended starting dose is 0.5 mg orally before each meal if HbA is less than 8%; and 1 mg or 2 mg orally before each meal if HbA is 8% or greater. ( 2.1) The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. ( 2.1) The patient’s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved. At least one week should elapse to assess response after each dose adjustment. ( 2.1) Instruct patients to skip the dose of repaglinide tablets if a meal is skipped. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced. ( 2.1, 5.1) Instruct patients to take repaglinide tablets within 30 minutes before meals. ( 2.1) In patients with severe renal impairment (CrCl = 20 mL/min to 40 mL/min), recommended starting dose is 0.5 mg orally before each meal. ( 2.2) Dose modifications are required when used concominantly with some medications. ( 2.3, 7) DOSAGE FORMS AND STRENGTHS Tablets: 0.5 mg, 1 mg, 2 mg ( 3) CONTRAINDICATIONS Concomitant use with gemfibrozil ( 4) Known hypersensitivity to repaglinide or any inactive ingredients ( 4) WARNINGS AND PRECAUTIONS Hypoglycemia: Repaglinide tablets may cause hypoglycemia. Skip the scheduled dose of repaglinide tablets if a meal is skipped to reduce the risk of hypoglycemia. Reduce the dose o Read the complete document